Long-term Clinical Outcomes of XXXX : Results of an International Registry.

@entity1 @entity82 @entity548 @entity2067 @entity5 @entity1031 @entity1575 @entity715
IMPORTANCE: Little information is available on the long-term clinical outcome of @entity1 with @entity715 ( @entity715 ). OBJECTIVE: To assess the incidence rates of @entity548 , @entity715 events, and mortality in a large international cohort of @entity1 with @entity715 . DESIGN, SETTING, AND @entity1 : A prospective cohort study was conducted beginning May 2, 2008, and completed January 30, 2014, at hospital-based centers specialized in the management of @entity1031 ; a 2-year follow-up period was completed January 30, 2014, and data analysis was conducted from July 1, 2014, to February 28, 2015. @entity1 included 604 consecutive @entity1 with objectively diagnosed @entity715 ; there were no exclusion critieria. Information was gathered on baseline characteristics, risk factors, and antithrombotic treatment. Clinical outcomes during the follow-up period were documented and reviewed by a central adjudication committee. MAIN OUTCOMES AND MEASURES: Major @entity548 , defined according to the International Society on @entity715 and Hemostasis; @entity548 requiring hospitalization; @entity715 events, including venous and arterial @entity715 ; and all-cause mortality. RESULTS: Of the 604 @entity1 (median age, 54 years; 62.6% males), 21 (3.5%) did not complete follow-up. The most common risk factors for @entity715 were @entity1575 (167 of 600 @entity1 [27.8%]) and solid @entity5 (136 of 600 [22.7%]); the most common sites of @entity715 were the portal vein (465 of 604 [77.0%]) and the mesenteric veins (266 of 604 [44.0%]). Anticoagulation was administered to 465 @entity1 in the entire cohort (77.0%) with a mean duration of 13.9 months; 175 of the anticoagulant group (37.6%) received parenteral treatment only, and 290 @entity1 (62.4%) were receiving @entity2067 antagonists. The incidence rates (reported with 95% CIs) were 3.8 per 100 @entity1 -years (2.7-5.2) for major @entity548 , 7.3 per 100 @entity1 -years (5.8-9.3) for @entity715 events, and 10.3 per 100 @entity1 -years (8.5-12.5) for all-cause mortality. During anticoagulant treatment, these rates were 3.9 per 100 @entity1 -years (2.6-6.0) for major @entity548 and 5.6 per 100 @entity1 -years (3.9-8.0) for @entity715 events. After treatment discontinuation, rates were 1.0 per 100 @entity1 -years (0.3-4.2) and 10.5 per 100 @entity1 -years (6.8-16.3), respectively. The highest rates of major @entity548 and @entity715 events during the whole study period were observed in @entity1 with @entity82 (10.0 per 100 @entity1 -years [6.6-15.1] and 11.3 per 100 @entity1 -years [7.7-16.8], respectively); the lowest rates were in @entity1 with @entity715 secondary to transient risk factors (0.5 per 100 @entity1 -years [0.1-3.7] and 3.2 per 100 @entity1 -years [1.4-7.0], respectively). CONCLUSIONS AND RELEVANCE: Most @entity1 with @entity715 have a substantial long-term risk of @entity715 events. In @entity1 with @entity82 , this risk must be balanced against a similarly high risk of major @entity548 . Anticoagulant treatment appears to be safe and effective in most @entity1 with @entity715 .
